Log in

Relevant bibliographies by topics / Omeprazole suspension / Journal articles

To see the other types of publications on this topic, follow the link: Omeprazole suspension.

Journal articles on the topic 'Omeprazole suspension'

Author: Grafiati

Published: 4 June 2021

Last updated: 15 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Omeprazole suspension.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Jackson, Remonica, Paul Lewis, and Stacy D. Brown. "Comparative Stability of Compounded Omeprazole Suspension Versus Commercial Omeprazole Kit When Stored in Oral Syringes Under Refrigerated Conditions." Journal of Pharmacy Technology 36, no. 5 (June 26, 2020): 179–86. http://dx.doi.org/10.1177/8755122520935532.

Full text

Abstract:

Background: Omeprazole is a proton pump inhibitor used to manage gastrointestinal disorders. Special populations may require omeprazole to be given as an oral suspension. Objective: The purpose of this project was to compare the stability of omeprazole in the FIRST kit product to a traditionally compounded omeprazole suspension, when stored in refrigerated unit-dosed syringes. NG tube delivery of the 2 products was also investigated. Methods: Five batches of compounded omeprazole oral suspension and 5 kits of FIRST-Omeprazole were prepared to an initial concentration of 2 mg/mL. Suspensions were aliquoted into 5-mL doses in clear plastic oral syringes, and stored at 2-8 °C. Syringes from each batch were analyzed at baseline and after 7, 14, 21, and 30 days for omeprazole potency using HPLC. To assess suitability for NG tube administration, 20 mL of each suspension were administered through NG tubes (8Fr, 10Fr, and 18Fr), and percent omeprazole recovery assessed. Results: The chemical potency remained within 90-110% for 14 days and 30 days for compounded samples and FIRST-Omeprazole samples, respectively. There was a statistically significant difference in initial concentration; 1.89 mg/mL versus 1.98 mg/mL for compounded and FIRST-Omeprazole, respectively. After 30 days, FIRST-Omeprazole demonstrated 97.20% API recovery. Neither suspension experienced statistically significant loss of potency following NG tube passage. Conclusion: FIRST-Omeprazole suspension may be stored in refrigerated clear luer-lock oral syringes for 30 days. Traditionally compounded omeprazole suspension should be used within 14 days. Both suspensions are suitable for NG tube administration.

APA, Harvard, Vancouver, ISO, and other styles

2

&NA;. "Omeprazole/Antacid-Powder Suspension ??? Santarus." Drugs in R & D 5, no. 6 (2004): 349–50. http://dx.doi.org/10.2165/00126839-200405060-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

&NA;. "Omeprazole/Antacid-Powder Suspension ??? Santarus." Drugs in R & D 5, no. 4 (2004): 234–35. http://dx.doi.org/10.2165/00126839-200405040-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Song, Jessica C., Robert A. Quercia, Chengde Fan, James Tsikouris, and C. Michael White. "Pharmacokinetic comparison of omeprazole capsules and a simplified omeprazole suspension." American Journal of Health-System Pharmacy 58, no. 8 (April 15, 2001): 689–94. http://dx.doi.org/10.1093/ajhp/58.8.689.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Rahić, Ognjenka, Edina Vranić, Jasmina Hadžiabdić, Merima Sirbubalo, and Amina Tucak. "Compounded omeprazole suspension - stable or not?" Macedonian Pharmaceutical Bulletin 66, no. 03 (October 29, 2020): 143–44. http://dx.doi.org/10.33320/maced.pharm.bull.2020.66.03.071.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

&NA;. "Omeprazole suspension prevents stress-induced GI bleeding." Inpharma Weekly &NA;, no. 1069 (January 1997): 16. http://dx.doi.org/10.2165/00128413-199710690-00025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Phillips, Jeffrey O., Michael Metzler, and Kjel Johnson. "THE STABILITY OF SIMPLIFIED OMEPRAZOLE SUSPENSION (SOS)." Critical Care Medicine 26, Supplement (January 1998): 101A. http://dx.doi.org/10.1097/00003246-199801001-00279.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

DiGiacinto, Jennifer L., Keith M. Olsen, Kimberly L. Bergman, and Eric B. Hoie. "Stability of Suspension Formulations of Lansoprazole and Omeprazole Stored in Amber-Colored Plastic Oral Syringes." Annals of Pharmacotherapy 34, no. 5 (May 2000): 600–605. http://dx.doi.org/10.1345/aph.19086.

Full text

Abstract:

OBJECTIVE: To determine the stability of lansoprazole and omeprazole suspensions at ambient and refrigerated temperatures using HPLC. DESIGN: The contents of lansoprazole and omeprazole capsules were suspended in separate flasks containing sodium bicarbonate 8.4% to concentrations of 3 and 2 mg/mL, respectively. The contents of each flask were drawn into six amber-colored oral syringes, with one-half of the syringes stored at 22 °C (ambient) and the other half at 4 °C. Lansoprazole and omeprazole concentrations were determined by a stability-indicating HPLC assay at baseline and at 4, 8, 12, and 24 hours, and on days 4, 7, 14, 21, 30, 45, and 60 after mixing. Both omeprazole and lansoprazole were considered stable if they retained ≤90% of the baseline drug concentration. RESULTS: Omeprazole was stable for up to 14 days at 22 °C and 45 days at 4 °C. Lansoprazole was stable for eight hours at 22 °C and for 14 days at 4 °C. CONCLUSIONS: When compared with ambient or refrigerated storage conditions, omeprazole was stable for a longer duration than lansoprazole. Pharmacists may use these results to guide compounding and storage of proton-pump inhibitor suspensions.

APA, Harvard, Vancouver, ISO, and other styles

9

Boscolo, Oriana, Francesco Perra, Leandro Salvo, Fabián Buontempo, and Silvia Lucangioli. "Formulation and Stability Study of Omeprazole Oral Liquid Suspension for Pediatric Patients." Hospital Pharmacy 55, no. 5 (April 25, 2019): 314–22. http://dx.doi.org/10.1177/0018578719844704.

Full text

Abstract:

Objectives: To develop and to study the physicochemical and microbiological stability of omeprazole liquid oral formulations used as therapeutic agent in many acid-related disorders, for pediatric use. Furthermore, to optimize and validate a stability-indicating high-performance liquid chromatography (HPLC) method for the analysis of omeprazole in the studied formulations. Method: Oral liquid suspensions of omeprazole were prepared at 2 mg/mL using crushed omeprazole pellets (formulation A) and pure omeprazole (formulation B) with a complete vehicle including humectant, suspending, sweetening, antioxidant, and flavoring agents. Samples were stored at 4°C and 25°C. Omeprazole content of each formulation was analyzed in triplicate using micro-HPLC at 0, 3, 7, 14, 30, 60, 90, 120, and 150 days. Other parameters were also determined, such as appearance, pH, resuspendibility, and viscosity. Microbiological studies were conducted according to the United Stated Pharmacopeia (USP) guidelines for non-sterile products. Results: Formulation A stayed physicochemical and microbiologically stable at refrigerated (4°C) conditions during at least 150 days and it only stayed stable during 14 days at 25°C. Formulation B was stayed physicochemical and microbiologically stable at refrigerated (4°C) conditions at least 90 days, but it is not recommended to store at 25°C for more than 1 day. Conclusions: Formulation A and formulation B can be stored for at least 150 and 90 days, respectively, at refrigerated conditions. Formulation A can be stored at room temperature for 14 days. Both formulations are perfectly suitable for pediatric patients who are usually notable to swallow solid oral formulations. The proposed analytical method was suitable for the study of stability of different formulations.

APA, Harvard, Vancouver, ISO, and other styles

10

Morrison, Jordan T., Ralph A. Lugo, Jim C. Thigpen, and Stacy D. Brown. "Stability of Extemporaneously Prepared Lansoprazole Suspension at Two Temperatures." Journal of Pediatric Pharmacology and Therapeutics 18, no. 2 (January 1, 2013): 122–27. http://dx.doi.org/10.5863/1551-6776-18.2.122.

Full text

Abstract:

OBJECTIVE The purpose of this study was to examine the stability of a generic lansoprazole product in a 3 mg/mL sodium bicarbonate suspension under room temperature and refrigerated conditions. METHODS Lansoprazole suspensions (3 mg/mL) were prepared in triplicate using an 8.4% sodium bicarbonate vehicle for each storage condition (room temperature and refrigerated). During 1 month, samples from each replicate were periodically removed and analyzed for lansoprazole concentration by liquid chromatography–tandem mass spectrometry (LC-MS/MS). Each sample was spiked with 10 mg/L omeprazole to serve as the internal standard. A positive electrospray LC-MS/MS method was validated over the calibration range of 5 to 25 mg/L using Food and Drug Administration Guidance. The identities of the analyte and internal standard in the samples were verified by monitoring the MS/MS transitions of m/z 370 to m/z 252 and m/z 346 to m/z 198 for lansoprazole and omeprazole, respectively. Additionally, the pH of the suspensions was monitored throughout the study. RESULTS The stability of lansoprazole in the oral sodium bicarbonate suspension under refrigeration is compromised prior to what has been previously reported in the literature. Samples kept at room temperature lost >10% of the lansoprazole after 48 hours compared with the refrigerated samples, which maintained integrity up to 7 days. No statistically significant difference was found between the pH of the room temperature and refrigerated suspension samples, indicating that this factor is not the cause for the differences in stability at these two conditions. CONCLUSIONS This study suggests that the extemporaneously compounded lansoprazole oral suspension prepared in 8.4% sodium bicarbonate should not be stored in plastic oral syringes longer than 48 hours at room temperature and no longer than 7 days when refrigerated. These data indicate an expiration time earlier than that previously reported for the refrigerated product (14 days).

APA, Harvard, Vancouver, ISO, and other styles

11

Freeman, Kevin L., and May S. Trezevant. "Interaction between liquid protein solution and omeprazole suspension." American Journal of Health-System Pharmacy 66, no. 21 (November 1, 2009): 1901–2. http://dx.doi.org/10.2146/ajhp090425.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Kimbel, KarlH. "Suspension of licence for intravenous omeprazole in Germany." Lancet 344, no. 8924 (September 1994): 756. http://dx.doi.org/10.1016/s0140-6736(94)92247-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Sharma, Virender K., Byron Peyton, Toni Spears, Jean-Pierre Raufman, and Colin W. Howden. "Absorption of omeprazole (Om) is significantly impaired when given as simplified omeprazole suspension (SOS)." Gastroenterology 118, no. 4 (April 2000): A1305. http://dx.doi.org/10.1016/s0016-5085(00)81078-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Johnson, Cary E., Mary Petrea Cober, and Jennifer L. Ludwig. "Stability of Partial Doses of Omeprazole–Sodium Bicarbonate Oral Suspension." Annals of Pharmacotherapy 41, no. 12 (December 2007): 1954–61. http://dx.doi.org/10.1345/aph.1k246.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Haizlip, Julie A., Ralph A. Lugo, Jared J. Cash, and Donald D. Vernon. "Failure of nasogastric omeprazole suspension in pediatric intensive care patients." Pediatric Critical Care Medicine 6, no. 2 (March 2005): 182–87. http://dx.doi.org/10.1097/01.pcc.0000154953.12594.9e.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Sultana, Nashid, Md Ismail Khan, Nasim Ahmed, Md Shakil Akhter, and Azmary Momtaz. "Comparative Gastro-Protective Effects of Nigella sativa (Kalojira) and Omeprazole against Aspirin Induced Gastric Ulcer in Albino Rats." Delta Medical College Journal 4, no. 2 (August 19, 2016): 61–66. http://dx.doi.org/10.3329/dmcj.v4i2.29371.

Full text

Abstract:

Background: Nigella sativa seeds have been in use as a natural remedy for over thousands of years in various parts of the world. These seeds are reported to have beneficial effects almost on every system of the body.Objective: To evaluate the gastro-protective effect of Nigella sativa on aspirin induced gastric ulcer with comparison to omeprazole.Materials and method: This experimental study was carried out in the department of Pharmacology and Therapeutics, Dhaka Medical College, Dhaka, Bangladesh in collaboration with the department of Pathology, Delta Medical College, Dhaka, Bangladesh. A total number of 30 healthy albino rats were used in this study. The experiment was divided into 2 parts: Experiment-1 and Experiment-2. Experiment-1 comprised of 12 rats: Group-A and Group-B having 6 rats in each group. Ulcer was produced by administration of aqueous suspension of aspirin (200 mg/kg body wt) in Group-B where Group-A served as control and was provided with normal saline (2 ml/kg body wt). All the rats were sacrificed after 4 hrs to confirm gastric ulcer by histopathology. Experiment-2 comprised of 18 rats: Group-C, Group-D and Group-E having 6 rats in each group. Group-C served as disease control group and provided with normal saline (2 ml/kg body wt). Group-D was provided with alcoholic extract of Nigella sativa (150 mg/kg body wt) and Group-E was provided with omeprazole suspension (20 mg/kg body wt). After 8 days of treatment, animals were fasted for 24 hrs. Then aqueous suspension of aspirin (200 mg/kg body wt) was administered and after 4 hrs all rats were sacrificed. Gross and microscopic examinations were performed to evaluate the results.Results: Aspirin caused marked gastric damage in negative control group which was prevented in omeprazole suspension and Nigella sativa extract treated groups significantly. The protective effect was maximum with omeprazole followed by alcoholic extract of Nigella sativa.Conclusion: Alcoholic extract of Nigella sativa showed significant protection against aspirin induced gastric ulcer in rats as compared to omeprazole.Delta Med Col J. Jul 2016 4(2): 61-66

APA, Harvard, Vancouver, ISO, and other styles

17

Petrželová, Markéta, Petr Horák, Anežka Hordějčuková, and Ludmila Matysová. "Omeprazole suspension 2 mg/ml - a new dosage form for pediatric use." Praktické lékárenství 13, no. 1 (March 1, 2017): 18–20. http://dx.doi.org/10.36290/lek.2017.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Burnett, Jane E., and Ethan R. Balkin. "Stability and viscosity of a flavored omeprazole oral suspension for pediatric use." American Journal of Health-System Pharmacy 63, no. 22 (November 15, 2006): 2240–47. http://dx.doi.org/10.2146/ajhp060026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Bergman, Kimberly L., Stuart Kaufman, Dean Collier, Jill A. Rebuck, Cindy Brown, and Keith M. Olsen. "PHARMACODYNAMICS OF OMEPRAZOLE SUSPENSION IN CRITICALLY ILL PEDIATRIC LIVER/INTESTINAL TRANSPLANT PATIENTS." Critical Care Medicine 27, Supplement (January 1999): 171A. http://dx.doi.org/10.1097/00003246-199901001-00513.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Lau, Bonnie, Uma Khazanie, Emily Rowe, and Karen Fauman. "How a Drug Shortage Contributed to a Medication Error Leading to Baclofen Toxicity in an Infant." Journal of Pediatric Pharmacology and Therapeutics 21, no. 6 (December 1, 2016): 527–29. http://dx.doi.org/10.5863/1551-6776-21.6.527.

Full text

Abstract:

We report the case of a 4-month-old girl who developed encephalopathy, seizures, and respiratory compromise as a result of baclofen toxicity. After some investigation, the accidental ingestion of baclofen was caused by an error in compounding the patient's prescribed omeprazole with baclofen rather than sodium bicarbonate at a retail pharmacy. This error occurred because these two drugs, which were available as powders, were located side by side on the pharmacy shelf. The pharmacist further reported that their normal practice was to use injectable sodium bicarbonate rather than powder to compound an omeprazole suspension; however, the injectable form was not available due to a national shortage. This report demonstrates how a drug shortage contributed to severe clinical consequences and intensive care hospitalization of a patient. It also highlights the need for system improvement to minimize drug shortages.

APA, Harvard, Vancouver, ISO, and other styles

21

Goldlust, Barry, Bonnie Hepburn, and Yun Hardiman. "NIGHTTIME DOSING OF OMEPRAZOLE IMMEDIATE-RELEASE ORAL SUSPENSION RAPIDLY DECREASES NOCTURNAL GASTRIC ACIDITY." American Journal of Gastroenterology 99 (October 2004): S39. http://dx.doi.org/10.14309/00000434-200410001-00116.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

IWAO, Kazunari, Hiroshi SAITOH, Kiyotaka TAKEDA, Yoshiteru AZUUMI, and Masahiko TAKADA. "Decreased Plasma Levels of Omeprazole after Coadministration with Magnesium-Aluminium Hydroxide Dry Suspension Granules." YAKUGAKU ZASSHI 119, no. 3 (1999): 221–28. http://dx.doi.org/10.1248/yakushi1947.119.3_221.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Karami, S., G. Dehghanzadeh, M. Haghighat, R. Mirzaei, and H. Rahimi. "Pharmacokinetic Comparison of Omeprazole Granule and Suspension Forms in Children: A Randomized, Parallel Pilot Trial." Drug Research 66, no. 03 (September 23, 2015): 165–68. http://dx.doi.org/10.1055/s-0035-1564101.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Sharma, Vasudeva, and Howden. "The effects on intragastric acidity of per-gastrostomy administration of an alkaline suspension of omeprazole." Alimentary Pharmacology & Therapeutics 13, no. 8 (August 1999): 1091–95. http://dx.doi.org/10.1046/j.1365-2036.1999.00589.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Phillips, Jeffrey O., Michael H. Metzler, Major Tina L. Palmieri, Roger E. Huckfeldt, and Nicola G. Dahl. "A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage." Critical Care Medicine 24, no. 11 (November 1996): 1793–800. http://dx.doi.org/10.1097/00003246-199611000-00006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Diefenthaeler, Helissara Silveira, Mariana Domingues Bianchin, Morgana Souza Marques, Julia Livia Nonnenmacher, Emanueli Tainara Bender, Júlia Gabrieli Bender, Samara Feil Nery, Luiz Carlos Cichota, and Irene Clemes Külkamp-Guerreiro. "Omeprazole nanoparticles suspension: Development of a stable liquid formulation with a view to pediatric administration." International Journal of Pharmaceutics 589 (November 2020): 119818. http://dx.doi.org/10.1016/j.ijpharm.2020.119818.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Coursol, Christian J., and Sabrina E. Sanzari. "Impact of Stress Ulcer Prophylaxis Algorithm Study." Annals of Pharmacotherapy 39, no. 5 (May 2005): 810–16. http://dx.doi.org/10.1345/aph.1d129.

Full text

Abstract:

BACKGROUND: In the intensive care unit at Royal Victoria Hospital, we noted that drugs prescribed for stress ulcer prophylaxis were not always indicated or optimal. Accordingly, we implemented an algorithm for stress ulcer prophylaxis to guide the medical team in their decisions. The agents selected for the algorithm were intravenous famotidine and omeprazole suspension or tablets, depending on the available administration route. OBJECTIVE: To evaluate the impact of a treatment algorithm on the appropriateness of prescriptions for stress ulcer prophylaxis. METHODS: A quasi-experimental—type evaluative study was conducted based on a pre-/post-intervention design without a concurrent control group. A total of 555 complete admissions met the selection criteria; 303 patients formed the pre-intervention group, and 252 made up the post-intervention group (exposed to the treatment algorithm). RESULTS: After implementation of the algorithm, the proportion of inappropriate prophylaxis was decreased (95.7% vs 88.2%; p = 0.033). The number of days of inappropriate prophylaxis was also reduced significantly (p = 0.013), as was the cost per patient (p = 0.003) for all admissions. However, no difference was observed when the subgroup of patients who received prophylaxis alone was studied (p = 0.098 and p = 0.918). The presence of bleeding was similar in both groups. CONCLUSIONS: Introduction by pharmacists of a treatment algorithm for stress ulcer prophylaxis in intensive care units allows a reduction of inappropriate prescriptions and thus a reduction in the cost of drugs. The use of omeprazole suspension seems to be an alternative to intravenous histamine2-inhibitors; however, a large-scale study is necessary to confirm the efficacy and safety of proton-pump inhibitors administered by an enteral tube.

APA, Harvard, Vancouver, ISO, and other styles

28

Orsi, Marina, Gabriela Donato, Veronica Busoni, Hector J. Arenoso, Jorge Soutric, Gabriela Naisberg, and Norberto G. Caruso. "M1885 Gastric Acid Suppression of a New Oral Powder Omeprazole Suspension for Infants with GERD. Pilot Study." Gastroenterology 136, no. 5 (May 2009): A—438—A—439. http://dx.doi.org/10.1016/s0016-5085(09)62020-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Foroutan, N., and A. Foroutan. "Financial impacts of using Omeprazole oral suspension for preventing upper Gastrointestinal bleeding early after Intensive Care admission." Value in Health 18, no. 3 (May 2015): A224. http://dx.doi.org/10.1016/j.jval.2015.03.1301.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Fuller, Patrick D., and Keith M. Olsen. "EFFECT OF ENTERAL TUBE FEEDINGS AND OMEPRAZOLE SUSPENSION ON THE ASSESSMENT OF OCCULT AND OVERT GASTRIC BLEEDING." Critical Care Medicine 30, Supplement (December 2002): A43. http://dx.doi.org/10.1097/00003246-200212001-00151.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

ATHERTON, J. C., D. J. E. CULLEN, G. E. KIRK, C. J. HAWKEY, and R. C. SPILLER. "Enhanced eradication of Helicobacter pylori by pre- versus post-prandial amoxycillin suspension with omeprazole: implications for antibiotic delivery." Alimentary Pharmacology & Therapeutics 10, no. 4 (August 1996): 631–35. http://dx.doi.org/10.1046/j.1365-2036.1996.37179000.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Nieto, Jorge E., Sharon Spier, Frank S. Pipers, Scott Stanley, Monica R. Aleman, Donald C. Smith, and Jack R. Snyder. "Comparison of paste and suspension formulations of omeprazole in the healing of gastric ulcers in racehorses in active training." Journal of the American Veterinary Medical Association 221, no. 8 (October 2002): 1139–43. http://dx.doi.org/10.2460/javma.2002.221.1139.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Afroz, Rumana, Md Ismail Khan, Kazi Afzalur Rahman, Mahbuba Jahan Lotus, Mir muhammad Shoyeb Shahabuddin, Tasnin Afrin, Nahid Yeasmin, and Kawsar Jahan Moon. "Histopathological Evaluation of Gastro Protective Effect of Trigonella Foenum Graecum Seed (Methi) and omeprazole in Experimentally Induced Gastric Ulcer in Rats." Journal of Dhaka Medical College 28, no. 1 (March 3, 2020): 67–75. http://dx.doi.org/10.3329/jdmc.v28i1.45759.

Full text

Abstract:

Context: Peptic ulcer is a common disorder of the stomach and duodenum. Bangladesh is a developing country with a very high point prevalence of duodenal ulcer disease (11.9%) and a H. pylori prevalence of more than 90% in asymptomatic adults and 80% in children at the age of 5 years. The multifactorial pathogenesis of peptic ulcers is secretion of gastric acid. The main therapeutic target is the control of this secretion using antacids, H2 receptor blockers (ranitidine, famotidine) or proton pump blockers (omeprazole and lansoprazole). However, nowadays, gastric ulcer therapy faces a major drawback because most of the drugs currently available in the market show limited efficacy against gastric diseases and are often associated with severe side effects. Thus, there is an urgent need to identify more effective and safe antiulcer agents. In this context, the use of medicinal plants for the prevention and treatment of different pathologies is in continuous expansion worldwide. From the ancient time, various plants were used in traditional medicine with reputation as efficacious remedies. The list of plant derived modern medicine is very long now. About 33% of the drugs produced in the developed countries are derived from plants. Trigonella foenum-graecum (Fenugreek, Methi) is one of them used in many parts of world. Preliminary study on animal showed that Trigonella foenum-graecum seed has significant gastro-protective effect. A study was carried out to demonstrate the gastro-protective effect of aqueous extract and ethanolic extract of Trigonella foenum-graecum seed (Fenugreek, Methi) and omeprazole on ethanol induced gastric ulcer in experimental rats. Material and Methods: The present study was performed on 24 (twenty four) rats which were divided randomly into 4 groups each having 6 rats in the Pharmacology Department of Dhaka Medical college, Dhaka. 1 ml of absolute ethanol (5ml/kg body wt.) was orally administered to all groups by gastric intubations to induce gastric ulcer in all groups except normal control. Omeprazole suspension (20mg/kg body wt) was used as synthetic anti ulcer drug in study. Aqueous and ethanolic extract of Trigonella foenum-graecum seed(500mg/kg body wt) were used respectively orally. Histopathological analysis was carried out to evaluate the gastroprotective activity of aqueous and ethanolic extract of Trigonella foenum-graecum seed and omeprazole on ethanol induced gastric ulcer in experimental rats. Result: Pretreatment with aqueous and ethanolic extract of Trigonella foenum-graecum seed (500mg/kg/body wt) showed very significant prevention in ethanol induced gastric ulcer. Results of the study showed that in case of ethanol treated rats gross examination showed a large amount of haemorrhagic lesions confined mostly in the gastric corpus. Histologically lesion involved about two-third of the mucosa layer and exfoliation of the mucosal cells was detected. Meanwhile, red blood cells were present in the gastric mucosa and edematous submucosa was discovered. However aqueous and ethanolic extract of Trigonella foenum-graecum seed significantly reduced the haemorrhagic lesions, tissue proliferation, infiltration of cells and sloughing induced by ethanol. This prevention was statistically very significant (P<0.001). Conclusion: The aqueous and ethanol extracts of Trigonella foenum-graecum seed and omeprazole possess gastro protective properties. J Dhaka Medical College, Vol. 28, No.1, April, 2019, Page 67-75

APA, Harvard, Vancouver, ISO, and other styles

34

Lasky, Michael R., Michael H. Metzler, and Jeffrey O. Phillips. "A Prospective Study of Omeprazole Suspension to Prevent Clinically Significant Gastrointestinal Bleeding from Stress Ulcers in Mechanically Ventilated Trauma Patients." Journal of Trauma: Injury, Infection, and Critical Care 44, no. 3 (March 1998): 527–33. http://dx.doi.org/10.1097/00005373-199803000-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Phillips, Jeffrey O., Michael H. Metzler, Roger E. Huckfeldt, and Keith Olsen. "A MULTICENTER, PROSPECTIVE, RANDOMIZED CLINICAL TRIAL OF CONTINUOUS INFUSION I.V. RANITIDINE VS. OMEPRAZOLE SUSPENSION IN THE PROPHYLAXIS OF STRESS ULCERS." Critical Care Medicine 26, Supplement (January 1998): 101A. http://dx.doi.org/10.1097/00003246-199801001-00280.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Castell, Donald, Barry Goldlust, Gaetano Morelli, Jacqueline Major, Theresa Gautille, and Bonnie Hepburn. "OMEPRAZOLE IMMEDIATE-RELEASE ORAL SUSPENSION IS MORE EFFECTIVE THAN PANTOPRAZOLE DELAYED-RELEASE CAPSULES IN REDUCING NIGHTTIME GASTRIC ACIDITY IN GERD PATIENTS." American Journal of Gastroenterology 99 (October 2004): S39—S40. http://dx.doi.org/10.14309/00000434-200410001-00117.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Dabiri, Yasamin, Fanak Fahimi, Hamidreza Jamaati, and Seyed Mohammad Hashemian. "The comparison of extemporaneous preparations of omeprazole, pantoprazole oral suspension and intravenous pantoprazole on the gastric pH of critically ill-patients." Indian Journal of Critical Care Medicine 19, no. 1 (January 2015): 21–26. http://dx.doi.org/10.4103/0972-5229.148635.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Froissart, M., P. Borensztein, P. Houillier, F. Leviel, J. Poggioli, E. Marty, M. Bichara, and M. Paillard. "Plasma membrane Na(+)-H+ antiporter and H(+)-ATPase in the medullary thick ascending limb of rat kidney." American Journal of Physiology-Cell Physiology 262, no. 4 (April 1, 1992): C963—C970. http://dx.doi.org/10.1152/ajpcell.1992.262.4.c963.

Full text

Abstract:

To characterize H+ transport mechanisms in a fresh suspension of rat medullary thick ascending limb (MTAL) tubules, we have monitored intracellular pH (pHi) with use of the fluorescent probe 2',7'-bis(carboxyethyl)-5,6-carboxyfluorescein. First, a Na(+)-H+ antiporter was identified in bicarbonate-free N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES)-buffered media at 25 degrees C. pHi recovery of Na-depleted acidified cells was dependent on extracellular sodium concentration, which was inhibited by amiloride in a manner consistent with simple competitive interaction with one external transport site (amiloride Ki = 1.5-2.1 x 10(-5) M); Na-induced pHi recovery of acidified cells was electroneutral since it was not affected by 5 or 100 mM extracellular potassium in the presence or absence of valinomycin. Second, at 37 degrees C, pHi recovery after acute intracellular acidification caused by 40 mM acetate addition to cell suspension was inhibited 36% by 200-400 nM bafilomycin A1, a macrolide antibiotic that specifically inhibits vacuolar-type H(+)-ATPase at submicromolar concentrations. In addition, amiloride-insensitive pHi recovery was inhibited by bafilomycin A1, 10(-3) M N-ethylmaleimide, and 10(-4) M preactivated omeprazole but not by 10(-5) M vanadate, 10(-4) M SCH 28080, or removal of extracellular potassium. Also, metabolic inhibition by absence of substrate, 10(-4) M KCN, or 5 x 10(-4) M iodoacetic acid inhibited amiloride-insensitive pHi recovery. The inhibitory effects of absence of metabolic substrate and iodoacetic acid were removed by reexposure to glucose and L-leucine and by exogenous ATP, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

APA, Harvard, Vancouver, ISO, and other styles

39

Chiu, C. T., C. M. Hsu, C. C. Wang, J. J. Chang, C. M. Sung, C. J. Lin, L. W. Chen, M. Y. Su, and T. H. Chen. "Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease." Alimentary Pharmacology & Therapeutics 38, no. 9 (September 11, 2013): 1054–64. http://dx.doi.org/10.1111/apt.12482.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Conrad, Steven A., Andrea Gabrielli, Benjamin Margolis, Andrew Quartin, J. Steven Hata, William O. Frank, Robert G. Bagin, James A. Rock, Bonnie Hepburn, and Loren Laine. "Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients." Critical Care Medicine 33, no. 4 (April 2005): 760–65. http://dx.doi.org/10.1097/01.ccm.0000157751.92249.32.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Dorman, T. "Randomized, Double-blind Comparison of Immediate-Release Omeprazole Oral Suspension Versus Intravenous Cimetidine for the Prevention of Upper Gastrointestinal Bleeding in Critically III Patients." Yearbook of Critical Care Medicine 2006 (January 2006): 197–98. http://dx.doi.org/10.1016/s0734-3299(08)70143-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

ASGARI, Behnoush, Fatemeh KERMANIAN, Nima DERAKHSHAN, Mohammadreza ASNA-ASHARI, Zahra Rouhani Nojede SADAT, and Somayeh YASLIANIFARD. "HONEY-DERIVED LACTOBACILLUS RHAMNOSUS ALLEVIATES HELICOBACTER PYLORI-INDUCED GASTRO-INTESTINAL INFECTION AND GASTRIC INFLAMMATION IN C57BL/6 MICE: AN IMMUNO-HISTOLOGIC STUDY." Arquivos de Gastroenterologia 55, no. 3 (September 2018): 279–82. http://dx.doi.org/10.1590/s0004-2803.201800000-70.

Full text

Abstract:

ABSTRACT BACKGROUND: Helicobacter pylori (H. pylori) has been introduced by since 1983 by Marshal and Warren to play the main role in the pathophysiology of gastritis and gastric ulcers. Almost half of the world population1 is infected by H. pylori. Current therapeutic regimen against H. pylori includes the use of a proton pump inhibitor plus two or more antibiotics. However, the efficacy of this regimen is decreasing mainly due to antibiotic resistance and side effects of medications. This fact has resulted in public interest in other therapeutic options and the role of probiotics merits special attention in this regard. OBJECTIVE: This study aims to evaluate the efficacy of honey-derived Lactobacillus rhamnosus on H. pylori-induced gastric inflammation and gastro-intestinal infection in C57BL/6 Mice. METHODS: The 24 C57BL/6 Mice were randomly divided into three groups of eight mice each. All the mice were fed with 1cc suspension containing 5*1010 CFU/ mL of ATCC43504 strains of H. pylori for 3 consecutive days, twice daily via polyethylene gavage tubes. At the end of 4th week, infection with H. pylori was confirmed with stool Ag (ELISA) and following sacrifice of one mouse from each group, histopathologic study confirmed gastritis. The groups were subjected to different therapies as stated, 1: without Bismuth (Bi), Omeprazole (Om) and L. rhamnosus prescription, 2: Bi, Om and Clarithromycin (Cl) and 3: Bi, Om plus 1cc of suspension of 109 CFU/mL of L. rhamnosus. After 2 weeks, the stool was analyzed for Ag and the mice were sacrificed for evaluation of histopathologic changes. RESULTS: Treatment with L. rhamnosus group provided Zero titer of stool Ag and was associated with improved gastric inflammation in all subjects, similar to the clarithromycin group. CONCLUSION: Honey-derived L. rhamnosus probiotics provides similar results as clarithromycin in terms of improvement of H. pylori infection and gastritis in C57BL/6 Mice model, without its cons of antibiotic resistance.

APA, Harvard, Vancouver, ISO, and other styles

43

Phillips, Jeffrey O., Keith M. Olsen, Jill A. Rebuck, Nick J. Rangnekar, Brent W. Miedema, and Michael H. Metzler. "A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers." American Journal of Gastroenterology 96, no. 2 (February 2001): 367–72. http://dx.doi.org/10.1111/j.1572-0241.2001.03522.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Wijaya, Dhani, Suharjono, Fendy Matulatan, and Elfri Padolo. "Analysis of stress ulcer prophylaxis drug regimentation in surgical patients." Journal of Basic and Clinical Physiology and Pharmacology 32, no. 4 (June 25, 2021): 645–49. http://dx.doi.org/10.1515/jbcpp-2020-0428.

Full text

Abstract:

Abstract Objectives The World Health Organization (WHO) estimated that more than 50% of drugs were prescribed incorrectly, including stress ulcer prophylaxis (SUP) drugs. Prescribing SUP drugs in incorrect doses and frequencies are considered irrational, and may affects to the effectivity of the therapy. This research aimed to assess the appropriateness of the SUP drugs regimentation in the inpatient surgery room at Dr. Soetomo Hospital, Surabaya, Indonesia. Methods This research was cross-sectional study and conducted for 4 weeks in 2019 in the inpatient surgery room of Dr. Soetomo Hospital. The population was SUP drugs that were prescribed in inpatient surgery room. Those SUP drugs with indications for the prevention of stress-induced ulcers that complied to the terms listed on the American Society of Health-System Pharmacists (ASHP) were included as the samples, and vice versa. The samples then assessed for their regimentation appropriateness using the dose and frequency standard of ASHP. Results There were 224 dose units taken as sample, from the total population of 1,404 SUP drugs. The result showed that as much as 48.2% of SUP medications were given to the patients in inappropriate regimentation. Of that number, all ranitidine injection were inappropriately regimented. On the contrary all omeprazole injection dose units were appropriately regimented, meanwhile the amount of appropriate regimentation of sucralfate suspension were 74.6%. Conclusions According to ASHP standard, the SUP drugs in the inpatient surgery room at Dr. Soetomo Hospital were mostly given in inappropriate regimentation. Further research is needed to explore how will those inappropriate regimentation affect on the efficacy of therapy in the patients.

APA, Harvard, Vancouver, ISO, and other styles

45

Kučerová, Kateřina, Veronika Reiská, František Švec, Lenka Kujovská Krčmová, and Ludmila Matysová. "Fast determination of omeprazole in extemporaneous suspensions used in paediatrics and stability studies." Analytical Methods 11, no. 4 (2019): 517–23. http://dx.doi.org/10.1039/c8ay02547a.

Full text

Abstract:

A simple and fast ultra-high-performance liquid chromatography method with UV detection for the separation and quantification of omeprazole and the impurities of omeprazole and methylparaben (the internal standard) in six extemporaneous suspensions has been developed and fully validated.

APA, Harvard, Vancouver, ISO, and other styles

46

Castell, D., R. Bagin, B. Goldlust, J. Major, and B. Hepburn. "Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease." Alimentary Pharmacology and Therapeutics 21, no. 12 (June 2005): 1467–74. http://dx.doi.org/10.1111/j.1365-2036.2005.02513.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

McAndrews, Kenneth L., and John H. Eastham. "Omeprazole and lansoprazole suspensions for nasogastric administration." American Journal of Health-System Pharmacy 56, no. 1 (January 1, 1999): 81. http://dx.doi.org/10.1093/ajhp/56.1.81.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

KATZ, P. O., F. K. KOCH, E. D. BALLARD, R. G. BAGIN, T. C. GAUTILLE, G. C. CHECANI, D. L. HOGAN, and V. S. V. PRATHA. "Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms." Alimentary Pharmacology & Therapeutics 25, no. 2 (January 3, 2007): 197–205. http://dx.doi.org/10.1111/j.1365-2036.2006.03191.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Lara, V. Gallardo, M. A. Ruiz, J. López-Viota, J. Salcedo, and A. V. Delgado. "Electrokinetic study of omeprazole drug in aqueous suspensions." Colloids and Surfaces A: Physicochemical and Engineering Aspects 218, no. 1-3 (May 2003): 21–26. http://dx.doi.org/10.1016/s0927-7757(02)00589-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Junaid, E. "A retrospective analysis of any trends in magnesium level for patients on omeprazole 10 mg/5 ml oral suspension from January to June 2012 (inclusive) in response to the MHRA Drug Safety Update April 2012." Archives of Disease in Childhood 98, no. 6 (May 9, 2013): e1-e1. http://dx.doi.org/10.1136/archdischild-2013-303935a.35.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!